Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0030567 (
Parkinson's disease
)
63,064
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Synphilin-1 is linked to
Parkinson's disease
(PD), based on its role as an alpha-synuclein (
PARK1
)-interacting protein and substrate of the ubiquitin E3 ligase Parkin (PARK2) and because of its presence in Lewy bodies (LB) in brains of PD patients. We found that overexpression of synphilin-1 in cells leads to the formation of ubiquitinated cytoplasmic inclusions supporting a derangement of the ubiquitin-proteasome system in PD. We report here a novel specific interaction of synphilin-1 with the regulatory proteasomal protein S6 ATPase (tbp7). Functional characterization of this interaction on a cellular level revealed colocalization of S6 and synphilin-1 in aggresome-like intracytoplasmic inclusions. Overexpression of synphilin-1 and S6 in cells caused reduced proteasomal activity associated with a significant increase in inclusion formation compared to cells expressing synphilin-1 alone. Steady-state levels of synphilin-1 in cells were not altered after cotransfection of S6 and colocalization of synphilin-1-positive inclusions with lysosomal markers suggests the presence of an alternative lysosomal degradation pathway. Subsequent immunohistochemical studies in brains of PD patients identified S6 ATPase as a component of LB. This is the first study investigating the physiological role of synphilin-1 in the ubiquitin proteasome system. Our data suggest a direct interaction of synphilin-1 with the regulatory complex of the proteasome modulating proteasomal function.
...
PMID:The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein--implications for Parkinson's disease. 1732 61
We tested the hypothesis that parkin polymorphisms (SNPs) and environmental exposure (EE) interact to reduce the age of onset of idiopathic
Parkinson disease
(PD). We prospectively and consecutively enrolled a total of 81 Italian PD patients. The diagnosis of PD was based on the UK
Parkinson's Disease
Society's brain bank criteria. Twenty-one patients with a positive family history for PD or tremor were excluded from the study. We collected information about medical history and EE.
PARK1
, PARK2 genes and PARK8 (exon 41) were screened. We detected one parkin mutation in a single patient and three parkin polymorphisms in a total of 25 patients; no alpha synuclein mutations, no common mutations of LRKK2 gene were found. The mutation-positive patient has been excluded from the study. The cohort of the remaining 59 patients has been divided into four subgroups, according to the presence/absence of parkin polymorphisms and the presence/absence of environmental factors-exposure. The age of onset of PD was significantly lower in patients with both SNPs and EE as compared to patients without (62.18+/-9.5 years versus 71.62+/-8 years, p=0.024; -13%). Patients with either SNPs or EE had an intermediate age of onset. The association of parkin polymorphisms and environmental exposure has a strong effect in lowering the age of onset of PD; the effect of environmental exposure or parkin polymorphisms alone seems to influence modestly the age of onset of PD. Individuals with environmental/occupational exposure should be screened for the presence of parkin SNPs.
...
PMID:Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease. 1733 4
The development of in vivo molecular imaging to evaluate the dopamine (DA) system with positron-emission tomography and single photon emission computed tomography has been of key importance on monitoring in vivo nigrostriatal neuronal loss in
Parkinson's disease
(PD), mostly through assessments of pre- and post-synaptic DA receptors. The discoveries of genes related to hereditary forms of parkinsonism (
PARK1
, PARK2, PARK6, PARK7 and PARK8) have increased our understanding either of distinct subtypes of clinical expression in PD or its etiology. This article revises current data on molecular neuroimaging of genetic forms of parkinsonism comparing and contrasting its main features with the classical sporadic forms. Awareness of the spectrum variance in the genotype and its respective PD phenotype are useful to distinguish different pathophysiological mechanisms of PD.
...
PMID:Molecular imaging in hereditary forms of parkinsonism. 1738 81
Studies of familial forms of
Parkinson's disease
(PD) have identified a growing number of genes that derive from the loci given the nomenclature
PARK1
-PARK13 (OMIM 168600). The alpha-synuclein gene has been implicated in rare autosomal dominant PD because of either mis-sense mutations (
PARK1
) or gene multiplications (PARK4). Moreover, UCHL1 (PARK5), LRRK2 (PARK8) and HTRA2 (PARK13) have been identified as causative genes for autosomal dominant PD, whereas parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7) and ATP13A2 (PARK9) have been identified as causative genes for autosomal recessive PD. Neuropathological examination of the kindreds of
PARK1
/4 showed Lewy body pathology ranging from classic PD to diffuse Lewy body disease. The pathological findings of PARK3 are similar to those of classic PD. In contrast, autopsies of patients with PARK2 showed nigral cell loss without Lewy bodies, although exceptions have been reported. Several kindreds of PARK8 included cases with Lewy body pathology, tau pathology, or with nigral cell loss in the absence of obvious protein deposition. Ubiquitin-positive inclusions that are negative for alpha-synuclein and tau are also seen in some cases. Moreover, widespread Lewy body pathology was also reported in several cases of familial Alzheimer's disease with presenilin-1 mutations.
...
PMID:[Pathology of familial Parkinson's disease]. 1771 21
Parkinson's disease
(PD) is the second most common neurodegenerative disorder among elderly people. 5-10% of PD cases are familial and presumably hereditary forms. Based on the genes responsible for familial PD, genetic PD animal models were produced and provided invaluable information as to the pathogenetic mechanisms of PD. Missense mutations or gene multiplications of alpha-synuclein lead to autosomal dominant form of familial PD termed
PARK1
or PARK4, respectively. Transgenic (Tg) mice expressing mutant of wild-type alpha-synuclein replicated main clinical features of PD including Lewy body-like aggregate formation. Inactivation of Parkin E3 enzyme leads to autosomal recessive form of PD without Lewy body formation. We have identified Pael-R as a substrate of Parkin. Accumulation of Pael-R induced by Parkin deletion evokes endoplasmic reticulum (ER) stress, resulting in cell death in cultured cells, Pael-R Tg Drosophila and Parkin-knockout crossed with Pael-R Tg mice. Recently Parkin-deficient and PTEN-induced kinase 1 (PINK1)-deficient flies showed almost identical phenotype: muscle and sperm degeneration accompanied by mitochondrial abnormalities. PINK1 is the gene for PARK6, an autosomal recessive PD. Interestingly, overexpression of Parkin rescued the phenotype of PINK1-deleted fly and Parkin/PINK1 double knockout Drosophila did not aggravated the phenotype of either Parkin or PINK1 single knockouts, indicating that Parkin and PINK1 are located in the common signaling pathway, in which Parkin works downstream of PINK1. Further studies on familial PD animal models will elucidate the roles and relationships of ubiquitin-proteasome system, endoplasmic reticulum and mitochondria in the pathogenesis of PD.
...
PMID:[Animal models for familial Parkinson's disease]. 1821 Aug 41
Parkinson's disease
(PD) is a common neurodegenerative disorder in the aging population, affecting more than 1% over the age of 65 years. Certain rare forms of the disease are monogenic, representing 5-10% of PD patients, but there is increasing evidence that multiple genetic risk factors are important also for common forms of PD. To date, 13 genetic loci,
PARK1
-13, have been suggested for rare forms of PD such as autosomal dominant and autosomal recessive PD. At six of these loci, genes have been identified and reported by several groups to carry mutations that are linked to affected family members. Genes in which mutations have been linked to familial PD have also been shown to be candidate genes for idiopathic forms of PD, as those same genes may also carry other mutations that merely increase the risk. Four of the PARK genes, SNCA at
PARK1
, UCH-L1 at PARK5, PINK1 at PARK6 and LRRK2 at PARK8, have been implicated in sporadic PD. There are indeed multiple genetic risk factors that combine in different ways to increase or decrease risk, and several of these need to be identified in order to begin unwinding the causative pathways leading to the different forms of PD. In this review, we present the molecular genetics of PD that are understood today, to help explain the pathways leading to neurodegeneration.
...
PMID:Parkinson's disease: a genetic perspective. 1827 77
Synphilin-1 has been linked to
Parkinson's disease
(PD) based on its role as an alpha-synuclein (
PARK1
) and Parkin (PARK2) interacting protein and its presence in lewy bodies in brains of PD patients. We recently identified a R621C mutation in the synphilin-1 gene in German PD patients. Functional analyses revealed that mutant synphilin-1 increases cellular stress, however, the involved molecular signalling pathways are currently unknown. Using microarray based gene expression analysis of dopaminergic SH-SY5Y cells overexpressing wild type or R621C mutant synphilin-1 we investigated differentially regulated genes and signalling networks using the Ingenuity Pathways Analysis tool. We show specific effects of C621 mutant synphilin-1 on gene expression that correlate with its role as a susceptibility factor in PD. The most significantly regulated signalling network was defined by the tumor growth factor beta 1 (TGF-beta1) suggesting an involvement of synphilin-1 in TGF-beta mediated signalling pathways modulating the cellular stress response.
...
PMID:Microarray expression analysis reveals genetic pathways implicated in C621 synphilin-1-mediated toxicity. 1829 64
A biomarker (biological marker) is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenetic processes or pharmacological responses to a therapeutic intervention. Expectations are high for the development of biomarkers since they make it possible to achieve a significant improvement in the diagnosis and classification of diseases like
Parkinson's disease
. As a surrogate marker for clinical studies, a biomarker can also be used to determine the efficacy of novel therapeutic interventions, such as neuroprotective strategies, and for monitoring the progress of the disease. Imaging techniques ((18)F-DOPA PET, (123)I-beta-CIT SPECT, MIBG scintigraphy, functional imaging), clinical tests (e.g. hyposmia, micrography, hyperechogenicity, apomorphine test), biochemical markers (e.g. alpha-synuclein and neuromelanin antibodies, oxidative and mitochondrial markers) and genetic tests for hereditary forms (
PARK1
to PARK11) are evaluated for their suitability.
...
PMID:Early detection of Parkinson's disease: unmet needs. 1832 71
The presynaptic protein alpha-synuclein is involved in several neurodegenerative diseases, including
Parkinson's disease
(PD). In rare familial forms of PD, causal mutations (
PARK1
) as well as multiplications (PARK4) of the alpha-synuclein gene have been identified. In sporadic, idiopathic PD, abnormal accumulation and deposition of alpha-synuclein might also cause degeneration of dopaminergic midbrain neurons, the clinically most relevant neuronal population in PD. Thus, cell-specific quantification of alpha-synuclein expression-levels in dopaminergic neurons from idiopathic PD patients in comparison to controls would provide essential information about contributions of alpha-synuclein to the etiology of PD. However, a number of previous studies addressing this question at the tissue-level yielded varying results regarding alpha-synuclein expression. To increase specificity, we developed a cell-specific approach for mRNA quantification that also took into account the important issue of variable RNA integrities of the individual human postmortem brain samples. We demonstrate that PCR -amplicon size can confound quantitative gene-expression analysis, in particular of partly degraded RNA. By combining optimized UV-laser microdissection- and quantitative RT-PCR-techniques with suitable PCR assays, we detected significantly elevated alpha-synuclein mRNA levels in individual, surviving neuromelanin- and tyrosine hydroxylase-positive substantia nigra dopaminergic neurons from idiopathic PD brains compared to controls. These results strengthen the pathophysiologic role of transcriptional dysregulation of the alpha-synuclein gene in sporadic PD.
...
PMID:Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. 1833 41
Recent progresses in the pathogenesis of sporadic
Parkinson's disease
(PD) and genetics of familial PD are reviewed. There are common molecular events between sporadic and familial PD, particularly between sporadic PD and
PARK1
-linked PD due to alpha-synuclein (SNCA) mutations. In sporadic form, interaction of genetic predisposition and environmental factors is probably a primary event inducing mitochondrial dysfunction and oxidative damage resulting in oligomer and aggregate formations of alpha-synuclein. In
PARK1
-linked PD, mutant alpha-synuclein proteins initiate the disease process as they have increased tendency for self-aggregation. As highly phosphorylated aggregated proteins are deposited in nigral neurons in PD, dysfunctions of proteolytic systems, i.e. the ubiquitin-proteasome system and autophagy-lysosomal pathway, seem to be contributing to the final neurodegenerative process. Studies on the molecular mechanisms of nigral neuronal death in familial forms of PD will contribute further on the understanding of the pathogenesis of sporadic PD.
...
PMID:Progress in the pathogenesis and genetics of Parkinson's disease. 1842 56
<< Previous
1
2
3
4
5
Next >>